Member Exclusive INTERVIEW

#TalkingRegMed 7: Cell therapy and big pharma with Sven Kili, GSK

​In this exclusive video, Sven Kili, ‎VP and Head of Cell & Gene Therapy Development, GSK, explains why rare diseases are so amenable to treatment with cell therapies.

Go to the profile of RegMedNet
May 09, 2018
0
1

Please sign in or register for FREE

1 Comments

Go to the profile of James L. Sherley, M.D., Ph.D.
James L. Sherley, M.D., Ph.D. almost 2 years ago

Cell therapy production, tissue stem cell manufacturing in particular, is primarily limited by biology, not cost.

James Sherley at Asymmetrex